Project example 2: Schizophrenia
| Project type |
Cost-utility analysis for reimbursement application |
| Indication |
Schizophrenia |
| Intervention |
Anti-psychotic medication |
| Methods |
Discrete event simulation modelling |
| Countries |
- UK
- Germany
- Italy
- Spain
- Portugal
- Netherlands
- All Scandinavian countries
- All Baltic countries
- Canada
|
|
Deliverables |
- Health-economic model for schizophrenia disease progression
- Health-economic dossiers for reimbursement application in a large number of countries
|
| Publications |
- A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. Treur M, Heeg B, Moller HJ, Schmeding A, van Hout BA, BMC Health Serv Res 2009; 9(1): 32.
- Modelling approaches: the case of schizophrenia. Heeg BM, Damen J, Buskens E, Caleo S, de Charro F, van Hout BA. Pharmacoeconomics 2008; 26(8): 633-48.
- The cost-effectiveness of atypicals in the UK. Heeg B, Buskens E, Botteman M, Caleo S, Ingham M, Damen J, de Charro F, van Hout BA. Value Health 2008; 11(7): 1007-21.
- Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Chue PS, Heeg B, Buskens E, van Hout BA. Pharmacoeconomics 2005; 23 Suppl 1: 62-74.
- Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Laux G, Heeg B, van Hout BA, Mehnert A. Pharmacoeconomics 2005; 23 Suppl 1: 49-61.
- Modelling the treated course of schizophrenia: development of a discrete event simulation model. Heeg B, Buskens E, Knapp M, van Aalst G, Dries PJ, de Haan L, van Hout BA. Pharmacoeconomics 2005: 23 Suppl 1: 17-33.
|
We have developed a patient-level model to simulate the disease progression of schizophrenia under various treatment scenarios. The model structure was based on discrete event simulation (DES). The model simulates the course of illness of individual patients and is able to incorporate complex relationships between relevant patient characteristics, treatment decisions and outcomes. This property makes the model suitable to simulate schizophrenia in a heterogeneous patient population. Results of incremental cost-effectiveness analyses performed with the model have been reported in pharmacoeconomic dossiers for reimbursement applications in a large number of countries, and in a series of journal articles.
|
/import/assetmanager/8/858/Project 2.pdf,_blank
Summary presentation
Projects by service
Projects by disease area
|
